Get started
Author

Samuel Rack

Observed names: Rack, Samuel, S. Rack, Sam Rack
ORCID: 0000-0001-9587-6598
Observed ORCID: 0000-0001-9587-6598
OpenAlex ID: A5077177377
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer
2019 · Nadina Tinsley, Cong Zhou, et al. · The Oncologist · 201
PDF
Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation
2022 · Laura Feeney, Brindley Hapuarachi, et al. · Oral Oncology · 32
PDF
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma
2020 · Helen Adderley, Samuel Rack, et al. · Oral Oncology · 25
PDF
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer
2022 · N. Tinsley, C. Zhou, et al. · ESMO Open · 13
Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer
2022 · Samuel Rack, Laura Feeney, et al. · Cancers · 12
PDF
KDM6A, ARID1A and SETD2 loss-of-function mutations as prognostic biomarkers and their association with sites of metastatic progression in locally-advanced, recurrent or metastatic adenoid cystic carcinoma
2025 · Sam Rack, Karan Patel, et al. · Oral Oncology · 6
Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study
2025 · Joseph Edward Haigh, Sam Rack, et al. · Current Oncology · 4
PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer.
2019 · Samuel Rack, Yonghan Li, et al. · Journal of Clinical Oncology · 4
Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.
2021 · Brindley Sonal Hapuarachi, Laura Feeney, et al. · Journal of Clinical Oncology · 3
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
2024 · Joseph Edward Haigh, Karan Patel, et al. · Current Oncology · 2
PDF
Gene expression patterns in adenoid cystic carcinoma with and without diffuse NOTCH1 intracellular domain (NICD1) immunohistochemistry staining
2023 · Karan Patel, Massimiliano Manzo, et al. · Oral Oncology · 2
Impact of tumour profiling on clinical trials in salivary gland cancer
2018 · Samuel Rack, Rizwana Rahman, et al. · Clinical Otolaryngology · 2
PDF
Association of quality of life with mortality in patients with adenoid cystic carcinoma using an internationally-validated QoL questionnaire (EQ-5D-5L)
2025 · Joseph Edward Haigh, Karan Patel, et al. · Oral Oncology · 1
904P Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
2024 · L. Spurgeon, G. Betts, et al. · Annals of Oncology · 1
PDF
Durable complete response rates following radiotherapy and immunotherapy combination in recurrent and metastatic head and neck squamous cell carcinoma: A retrospective single‐centre cohort study
2022 · Raj Khera, Laura Feeney, et al. · Clinical Otolaryngology · 1
PDF
The prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinoma.
2022 · Samuel Rack, Laura Feeney, et al. · Journal of Clinical Oncology · 1
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small cell lung cancer.
2021 · Nadina Tinsley, Natalie Cook, et al. · Journal of Clinical Oncology · 1
ELLA01-1: A study to determine the utility of TP53 mutations as a prognostic biomarker in adenoid cystic carcinoma.
2020 · Robert Metcalf, Khaireah Mubarak, et al. · Journal of Clinical Oncology · 1
Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation
2026 · Karan Patel, Joseph Edward Haigh, et al. · Cancers
PDF
Impact of tumor site and diagnostic pathway on stage at diagnosis: A population-based study of 5,638 salivary gland cancer patients (2013–2023).
2026 · Samuel Rack, Guy Betts, et al. · Journal of Clinical Oncology
The frequency and prognostic relevance of co-occurring TP53 mutation and NOTCH pathway activation in locally advanced, recurrent or metastatic adenoid cystic carcinoma
2026 · Syeda Malaika Haider, Joseph Edward Haigh, et al. · Oral Oncology
Improving diagnostic pathways for salivary gland cancer: addressing delays and enhancing early detection
2025 · Samuel Rack · British Journal of Oral and Maxillofacial Surgery
1416P Clinical and genomic characterisation of adenoid cystic carcinoma (ACC) of the respiratory tract and the major salivary gland
2025 · I. Read, J.E. Haigh, et al. · Annals of Oncology
1433P Proteomic analysis of immune matrix composition in type-I and type-II adenoid cystic carcinoma (ACC)
2025 · S. Kirkham, Z. Zhang, et al. · Annals of Oncology
58MO Advancing salivary gland cancer research: A multidisciplinary approach to addressing the unmet clinical need
2025 · R. Metcalf, I.S. Boon, et al. · ESMO Open
Works count: 40
Citation count: 312
H-index: 6
I10-index: 5
Year
Topic
Type